SCHEMBL4042923

SCHEMBL4042923

NC([C]=O)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140449 1.00
SCHEMBL5646565 0.97 EPHX1 (0.41)
SCHEMBL4040242 0.97 EPHX1 (0.41)
SCHEMBL7139724 0.88
SCHEMBL7139721 0.88
SCHEMBL28132670 0.88
SCHEMBL27683336 0.72
SCHEMBL2396925 0.72
SCHEMBL23795868 0.71 EPHX1 (0.35)
SCHEMBL6880531 0.70 EPHX1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102573879-A Cathepsin C inhibitors GLAXO GROUP LTD 2012-07-11 CN claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
US-6632795-B1 Treatment of cancer BASF AKTIENGESELLSCHAFT (DE) 2003-10-14 US claimed
EP-0981358-B1 DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES BASF AG (DE) 2003-05-28 EP claimed
EP-1021200-B1 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS BASF AG (DE) 2002-02-06 EP claimed
US-6103698-A USEFUL IN TREATING CANCER IN A MAMMAL; IN COMBINATION WITH PACLITAXEL AND TAXOTERE BASF AKTIENGESELLSCHAFT (DE) 2000-08-15 US claimed
EP-1021200-A1 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS BASF AKTIENGESELLSCHAFT (DE) 2000-07-26 EP claimed
EP-0981358-A1 DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES BASF AKTIENGESELLSCHAFT (DE) 2000-03-01 EP claimed
US-6015790-A Methods and compositions for treating rheumatoid arthritis BASF AKTIENGESELLSCHAFT (DE) 2000-01-18 US claimed
WO-1999017792-A1 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS BASF AKTIENGESELLSCHAFT (DE) 1999-04-15 WO claimed
WO-1999017709-A2 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS BASF AKTIENGESELLSCHAFT (DE) 1999-04-15 WO claimed
US-5831002-A HYBRID POLYPEPTIDE BASF AKTIENGESELLSCHAFT (DE) 1998-11-03 US claimed
WO-1998040092-A1 DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES BASF AKTIENGESELLSCHAFT (DE) 1998-09-17 WO claimed
CN-102573879-A Cathepsin C inhibitors GLAXO GROUP LTD 2012-07-11 CN disclosed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-5831002-A HYBRID POLYPEPTIDE BASF AKTIENGESELLSCHAFT (DE) 1998-11-03 US disclosed
WO-1998040092-A1 DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES BASF AKTIENGESELLSCHAFT (DE) 1998-09-17 WO disclosed